Form 4: Nurix Therapeutics Executive Gwenn Hansen Reports Stock Transactions
SEC Form 4 Filing
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.
Summary
- On July 30, 2024, Gwenn Hansen, the Chief Scientific Officer of Nurix Therapeutics, engaged in multiple transactions involving the company's stock.
- Hansen acquired 3,207, 2,000, and 3,750 shares of common stock through the vesting of restricted stock units (RSUs).
- Simultaneously, Hansen disposed of 3,408 shares of common stock at a weighted average price of $20.6677 to cover tax withholding obligations related to the vesting of RSUs.
- Following these transactions, Hansen directly owns 45,150 shares of Nurix Therapeutics common stock, 19,241 restricted stock units from one grant, 14,000 restricted stock units from another grant, and 41,250 restricted stock units from a third grant.
- The sales were mandated by Nurix Therapeutics' equity incentive plans to cover tax obligations and do not represent discretionary trades.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing detailing stock transactions related to RSU vesting and tax obligations. There's no indication of unusual activity or concern.
Positives
- The vesting of RSUs indicates that Hansen is meeting the service requirements of the equity incentive plans.
Negatives
- The sale of shares to cover tax obligations reduces Hansen's holdings in the company, although this is a standard practice.
Risks
- There are no specific risks highlighted in this document.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine stock activity related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| April 30, 2022 | First quarterly vesting increment for 3,207 RSUs. |
| July 30, 2023 | First quarterly vesting increment for 2,000 RSUs. |
| July 30, 2024 | Date of the reported transactions: acquisition of stock through RSU vesting and sale of stock to cover tax obligations; first quarterly vesting increment for 3,750 RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.